Notch inhibitors

It is known that some genes cause or contribute to the initiation and/or growth of cancer, and one area of research is whether blocking the action of those genes can stop or prevent the cancer. The Notch gene was first found in 1917 and now it turns out that the gene is implicated in a signaling system that is part of tumor growth.

Cell membrane surfaces have receptors now referred to as Notch receptors. In scientific literature there are referred to as Notch1 (or more formally Notch homolog 1 translocation-associated receptor), Notch2, Notch3, and Notch4.

A bunch of potential notch inhibitors are being investigated for their effects on cancer proliferation. There is an interest in combining them with hedgehog inhibitors. Cancer stem cells – aka tumor-initiating cells – are an area in which scientists think notch inhibitors might be helpful. However, Nature reports that work done to date has found no substantial antitumor effect of notch inhibitors.  There are no notch inhibitor therapies in clinical use at this time.

Consequences of Disrupted Notch Signaling in Bladder Cancer.

Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer.

NOTCH pathway inactivation promotes bladder cancer progression.

NOTCH Decoys That Selectively Block DLL/NOTCH or JAG/NOTCH Disrupt Angiogenesis by Unique Mechanisms to Inhibit Tumor Growth

Changes in the regulation of the Notch signaling pathway are temporally correlated with regenerative failure in the mouse cochlea

Notch inhibitors for pulmonary arterial hypertension – SciBX Science Business Exchange

Notch inhibition reverses kidney failure – Nature